Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia
Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine‐induced peripheral neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N = 128) aged 1–1...
Saved in:
| Published in | Journal of the peripheral nervous system Vol. 20; no. 1; pp. 37 - 46 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Malden, USA
Wiley Periodicals, Inc
01.03.2015
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine‐induced peripheral neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N = 128) aged 1–18 years who received vincristine at one of four academic children's hospitals. VIPN assessments were obtained using the Total Neuropathy Score‐Pediatric Vincristine (TNS©‐PV), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE©), Balis© grading scale, and Pediatric Neuropathic Pain Scale©–Five (PNPS©‐5). Of children who provided a full TNS©‐PV score, 85/109 (78%) developed VIPN (TNS©‐PV ≥4). Mean TNS©‐PV, grading scale, and pain scores were low. CTCAE©‐derived grades 3 and 4 sensory and motor VIPN occurred in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months 8–12 despite decreasing dose density. VIPN was worse in older children. Partition cluster analysis revealed 2–3 patient clusters; one cluster (n = 14) experienced severe VIPN. In this population, VIPN occurs more commonly than previous research suggests, persists throughout the first year of treatment, and can be severe. |
|---|---|
| AbstractList | Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine-induced peripheral neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N=128) aged 1-18 years who received vincristine at one of four academic children's hospitals. VIPN assessments were obtained using the Total Neuropathy Score-Pediatric Vincristine (TNS©-PV), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE©), Balis© grading scale, and Pediatric Neuropathic Pain Scale©-Five (PNPS©-5). Of children who provided a full TNS©-PV score, 85/109 (78%) developed VIPN (TNS©-PV ≥4). Mean TNS©-PV, grading scale, and pain scores were low. CTCAE©-derived grades 3 and 4 sensory and motor VIPN occurred in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months 8-12 despite decreasing dose density. VIPN was worse in older children. Partition cluster analysis revealed 2-3 patient clusters; one cluster (n=14) experienced severe VIPN. In this population, VIPN occurs more commonly than previous research suggests, persists throughout the first year of treatment, and can be severe. Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia ( ALL ), can lead to vincristine‐induced peripheral neuropathy ( VIPN ). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N = 128) aged 1–18 years who received vincristine at one of four academic children's hospitals. VIPN assessments were obtained using the Total Neuropathy Score‐Pediatric Vincristine ( TNS ©‐ PV ), National Cancer Institute Common Terminology Criteria for Adverse Events ( CTCAE ©), Balis© grading scale, and Pediatric Neuropathic Pain Scale©–Five ( PNPS ©‐5). Of children who provided a full TNS ©‐ PV score, 85/109 (78%) developed VIPN ( TNS ©‐ PV ≥4). Mean TNS ©‐ PV , grading scale, and pain scores were low. CTCAE ©‐derived grades 3 and 4 sensory and motor VIPN occurred in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months 8–12 despite decreasing dose density. VIPN was worse in older children. Partition cluster analysis revealed 2–3 patient clusters; one cluster (n = 14) experienced severe VIPN . In this population, VIPN occurs more commonly than previous research suggests, persists throughout the first year of treatment, and can be severe. |
| Author | Thomas, Karin Chakraborty, Arindom Chiang, ChienWei Bridges, Celia M. Renbarger, Jamie Hutchinson, Raymond J. Ho, Richard H. Wells, Elizabeth M. Skiles, Jodi Li, Lang Lavoie Smith, Ellen M. |
| AuthorAffiliation | 1 School of Nursing, University of Michigan, Ann Arbor, MI, USA 5 Department of Pediatrics, Vanderbilt University, Nashville, TN, USA 4 Children’s National Health System, Washington, DC, USA 3 Department of Nursing, Children’s Hospital Colorado, Aurora, CO, USA 2 School of Medicine, Indiana University, Indianapolis, IN, USA |
| AuthorAffiliation_xml | – name: 5 Department of Pediatrics, Vanderbilt University, Nashville, TN, USA – name: 3 Department of Nursing, Children’s Hospital Colorado, Aurora, CO, USA – name: 4 Children’s National Health System, Washington, DC, USA – name: 2 School of Medicine, Indiana University, Indianapolis, IN, USA – name: 1 School of Nursing, University of Michigan, Ann Arbor, MI, USA |
| Author_xml | – sequence: 1 givenname: Ellen M. surname: Lavoie Smith fullname: Lavoie Smith, Ellen M. email: ellenls@med.umich.edu organization: School of Nursing, University of Michigan, MI, Ann Arbor, USA – sequence: 2 givenname: Lang surname: Li fullname: Li, Lang organization: School of Medicine, Indiana University, IN, Indianapolis, USA – sequence: 3 givenname: ChienWei surname: Chiang fullname: Chiang, ChienWei organization: School of Medicine, Indiana University, IN, Indianapolis, USA – sequence: 4 givenname: Karin surname: Thomas fullname: Thomas, Karin organization: Department of Nursing, Children's Hospital Colorado, CO, Aurora, USA – sequence: 5 givenname: Raymond J. surname: Hutchinson fullname: Hutchinson, Raymond J. organization: School of Nursing, University of Michigan, MI, Ann Arbor, USA – sequence: 6 givenname: Elizabeth M. surname: Wells fullname: Wells, Elizabeth M. organization: Children's National Health System, DC, Washington, USA – sequence: 7 givenname: Richard H. surname: Ho fullname: Ho, Richard H. organization: Department of Pediatrics, Vanderbilt University, TN, Nashville, USA – sequence: 8 givenname: Jodi surname: Skiles fullname: Skiles, Jodi organization: School of Medicine, Indiana University, IN, Indianapolis, USA – sequence: 9 givenname: Arindom surname: Chakraborty fullname: Chakraborty, Arindom organization: School of Medicine, Indiana University, IN, Indianapolis, USA – sequence: 10 givenname: Celia M. surname: Bridges fullname: Bridges, Celia M. organization: School of Nursing, University of Michigan, MI, Ann Arbor, USA – sequence: 11 givenname: Jamie surname: Renbarger fullname: Renbarger, Jamie organization: School of Medicine, Indiana University, IN, Indianapolis, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25977177$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS1URP_AgS-ALHHikNaOndi-INEVtFSlICiiN8txJsTbrBMcZ9t8e1y2XQES-GJL83tvZvz20Y7vPSD0nJJDms7R0o-HNKeUP0J7tMhVJkkudtKbyCJTXKpdtD-OS0KoUFQ9Qbt5oYSgQuyh4ZOJEYIfsfE1HmENwcUZ9w1eO2-DG6PzkDlfTxZqPKTq0EIwHfYwhX4wsZ2x89i2rqsDeHzjYouNnSLgbl4NbV91JnlY3MF0DStnnqLHjelGeHZ_H6Cv795eLk6z848n7xdvzjPLJeVZASVUheJMGVbbIq9KWklSNYrxSnJVAq952qYxVhpiCpvXokn7QUMKlstasgP0euM7TNUKags-prH1ENzKhFn3xuk_K961-nu_1rykRNA8Gby8Nwj9jwnGqJf9FHyaWdNSSsaIynmiXvzeZuv_8MMJeLUBbOjHMUCzRSjRd-nplJ7-lV5ij_5irYsmuv5uQtf9T3HjOpj_ba3PLr48KLKNIkULt1uFCde6FEwU-tvFib76fHb5gS2O9RX7CSc-veQ |
| CitedBy_id | crossref_primary_10_1097_AJP_0000000000000993 crossref_primary_10_1111_jns_12334 crossref_primary_10_1097_MPH_0000000000001604 crossref_primary_10_1007_s00432_020_03216_8 crossref_primary_10_1007_s00520_016_3441_6 crossref_primary_10_3390_cancers14030612 crossref_primary_10_1016_S2352_4642_18_30236_0 crossref_primary_10_1007_s00520_021_06059_2 crossref_primary_10_1016_j_blre_2020_100653 crossref_primary_10_1177_1078155217746228 crossref_primary_10_2217_pgs_2018_0093 crossref_primary_10_1016_j_ejpn_2017_12_019 crossref_primary_10_1093_bjaed_mkx018 crossref_primary_10_3389_fpsyg_2019_00818 crossref_primary_10_1016_j_ctrv_2016_09_005 crossref_primary_10_1016_j_ebiom_2020_103124 crossref_primary_10_1016_j_ncl_2020_06_002 crossref_primary_10_3389_fphar_2023_1213763 crossref_primary_10_7759_cureus_34979 crossref_primary_10_1016_j_jsampl_2024_100065 crossref_primary_10_1016_j_expneurol_2019_113090 crossref_primary_10_1111_bcp_15267 crossref_primary_10_1002_pon_70063 crossref_primary_10_1016_j_ijporl_2019_04_001 crossref_primary_10_3389_fphar_2021_771487 crossref_primary_10_1007_s00431_024_05638_9 crossref_primary_10_1097_AJP_0000000000001217 crossref_primary_10_1093_brain_awaa208 crossref_primary_10_3390_ijms23105515 crossref_primary_10_3389_fnmol_2017_00174 crossref_primary_10_1002_hem3_70092 crossref_primary_10_1093_brain_aww251 crossref_primary_10_1038_s41598_020_66815_y crossref_primary_10_7759_cureus_46063 crossref_primary_10_21682_2311_1267_2022_9_3_107_112 crossref_primary_10_1097_MPH_0000000000002707 crossref_primary_10_1007_s11764_025_01763_y crossref_primary_10_1016_j_soncn_2019_04_006 crossref_primary_10_1016_j_soncn_2019_04_007 crossref_primary_10_1097_PEP_0000000000000484 crossref_primary_10_1016_j_neurol_2020_11_001 crossref_primary_10_1038_s41598_022_08585_3 crossref_primary_10_1016_j_cnp_2024_01_005 crossref_primary_10_1111_apa_17092 crossref_primary_10_3390_jcm12020686 crossref_primary_10_1002_pbc_29550 crossref_primary_10_1093_jnci_djac095 crossref_primary_10_2298_SARH210813099R crossref_primary_10_1002_pbc_26204 crossref_primary_10_1016_j_apmr_2023_04_015 crossref_primary_10_33667_2078_5631_2024_32_50_54 crossref_primary_10_1002_ana_24951 crossref_primary_10_1038_s41525_024_00443_7 crossref_primary_10_1016_j_blre_2024_101254 crossref_primary_10_1200_JCO_2017_76_7871 crossref_primary_10_3390_jcm10143016 crossref_primary_10_5812_jjnpp_82793 crossref_primary_10_1002_pbc_26706 crossref_primary_10_1093_brain_awae071 crossref_primary_10_1002_hem3_124 crossref_primary_10_1097_j_pain_0000000000000953 crossref_primary_10_5812_ijp_11844 crossref_primary_10_1007_s10072_021_05576_6 crossref_primary_10_1016_j_pedn_2023_04_006 crossref_primary_10_1177_1043454220980253 crossref_primary_10_1007_s10616_022_00543_1 crossref_primary_10_1101_sqb_2018_83_037622 crossref_primary_10_1002_pbc_26677 crossref_primary_10_1002_pbc_27369 crossref_primary_10_1007_s00894_018_3611_1 crossref_primary_10_1016_j_expneurol_2020_113519 crossref_primary_10_1097_j_pain_0000000000001361 crossref_primary_10_33590_emjoncol_10310846 crossref_primary_10_1177_10781552211024727 crossref_primary_10_1016_S2352_3026_20_30064_8 crossref_primary_10_17340_jkna_2021_1_1 crossref_primary_10_1002_pbc_30634 crossref_primary_10_1007_s00520_019_05106_3 crossref_primary_10_1080_21678707_2016_1182908 crossref_primary_10_1177_1043454219845887 crossref_primary_10_3389_fphar_2017_00086 crossref_primary_10_3390_ijms251910389 crossref_primary_10_1097_j_pain_0000000000002485 crossref_primary_10_1016_j_jpain_2019_06_011 crossref_primary_10_1097_j_pain_0000000000000981 crossref_primary_10_1002_pbc_28681 crossref_primary_10_3390_ph17020144 crossref_primary_10_1097_MPH_0000000000001529 crossref_primary_10_2144_fsoa_2020_0044 crossref_primary_10_1007_s00280_019_03884_5 crossref_primary_10_3389_fonc_2021_710163 crossref_primary_10_1080_17474086_2020_1770591 crossref_primary_10_2152_jmi_68_232 crossref_primary_10_36740_WLek201908107 crossref_primary_10_1111_jhn_13273 crossref_primary_10_1080_08880018_2019_1677832 crossref_primary_10_52881_gsbdergi_1490198 crossref_primary_10_1111_pan_14324 crossref_primary_10_18786_2072_0505_2022_50_038 crossref_primary_10_2174_1568009621666210720142542 crossref_primary_10_1002_cam4_6550 crossref_primary_10_1016_j_bulcan_2018_07_009 crossref_primary_10_1212_CON_0000000000000873 crossref_primary_10_1016_j_pharmthera_2019_01_002 crossref_primary_10_1002_pbc_26652 crossref_primary_10_1177_0145561320924868 crossref_primary_10_1007_s10495_018_1508_1 crossref_primary_10_1016_j_critrevonc_2017_04_004 crossref_primary_10_1002_cpt_1324 crossref_primary_10_1016_j_intimp_2023_110046 crossref_primary_10_3389_fmolb_2022_1015746 crossref_primary_10_1007_s11764_020_00932_5 crossref_primary_10_1007_s40272_018_00324_4 crossref_primary_10_1242_jcs_260490 crossref_primary_10_1097_MPH_0000000000001220 crossref_primary_10_52420_2071_5943_2023_22_6_124_135 crossref_primary_10_46483_deuhfed_959493 crossref_primary_10_1177_1043454218762705 crossref_primary_10_5812_ans_149393 crossref_primary_10_1002_pbc_28264 crossref_primary_10_1016_j_soncn_2019_150984 crossref_primary_10_1016_j_bcp_2023_115630 crossref_primary_10_3389_fped_2020_526235 crossref_primary_10_1080_17425255_2021_1855141 crossref_primary_10_1200_OP_21_00796 crossref_primary_10_25259_IJPC_143_2023 crossref_primary_10_3390_ijms22084112 crossref_primary_10_1002_pbc_26525 crossref_primary_10_1016_j_clinph_2023_08_002 crossref_primary_10_1002_cpt_1179 crossref_primary_10_1038_s41598_024_65313_9 crossref_primary_10_1186_s12885_025_13751_7 crossref_primary_10_1097_MPH_0000000000001230 crossref_primary_10_3389_fnins_2019_00653 crossref_primary_10_1097_MPH_0000000000002202 crossref_primary_10_3389_fped_2022_980890 crossref_primary_10_1002_cam4_7422 crossref_primary_10_1016_j_ctarc_2021_100420 crossref_primary_10_1016_j_taap_2024_117134 crossref_primary_10_1097_j_pain_0000000000001444 crossref_primary_10_1002_pbc_26471 crossref_primary_10_1016_j_nbd_2019_104492 crossref_primary_10_1007_s40487_021_00168_y crossref_primary_10_1097_MPH_0000000000000825 crossref_primary_10_1097_ALN_0000000000001601 crossref_primary_10_1007_s00520_024_08484_5 crossref_primary_10_1158_1055_9965_EPI_21_0154 crossref_primary_10_33920_med_01_2402_09 |
| Cites_doi | 10.1023/A:1008344507482 10.1111/j.1529-8027.2010.00292.x 10.1007/BF00877252 10.1097/NCC.0b013e318299ad23 10.1002/cncr.20928 10.1124/dmd.106.009902 10.1007/BF01050259 10.1016/j.soncn.2009.03.013 10.1093/annonc/mds329 10.1111/j.1529-8027.2009.00230.x 10.1016/j.apmr.2013.03.009 10.1001/jama.2015.0894 10.1212/WNL.53.8.1660 10.1016/S0360-3016(99)00369-7 10.1046/j.1460-9592.2003.01142.x 10.1007/s00520-013-1981-6 10.1016/j.spen.2012.02.011 10.1002/pbc.22456 10.1002/pbc.22845 10.1007/s00520-012-1591-8 10.1212/01.WNL.0000154642.45474.28 10.1016/j.ejca.2009.12.008 10.1016/j.leukres.2013.09.018 10.1016/j.critrevonc.2011.04.012 10.1097/00043426-200304000-00010 10.1007/s11764-014-0375-1 10.1007/s12098-009-0254-3 10.1016/j.ncl.2006.11.001 10.1002/pbc.23039 10.1188/08.ONF.96-102 10.1111/j.1529-8027.2011.00351.x 10.1200/JCO.2012.47.8081 10.1182/blood-2012-04-418640 |
| ContentType | Journal Article |
| Copyright | 2015 Peripheral Nerve Society 2015 Peripheral Nerve Society. |
| Copyright_xml | – notice: 2015 Peripheral Nerve Society – notice: 2015 Peripheral Nerve Society. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 5PM |
| DOI | 10.1111/jns.12114 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1529-8027 |
| EndPage | 46 |
| ExternalDocumentID | PMC4610712 3715666541 25977177 10_1111_jns_12114 JNS12114 ark_67375_WNG_XRJTM3CB_X |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: R01 HD062484 – fundername: NCATS NIH HHS grantid: UL1 TR001108 – fundername: NICHD NIH HHS grantid: K12 HD068371 – fundername: NCATS NIH HHS grantid: UL1 TR000445 – fundername: NCATS NIH HHS grantid: KL2 TR000446 – fundername: NIGMS NIH HHS grantid: R01 GM099924 – fundername: NCATS NIH HHS grantid: UL1 TR000433 – fundername: NCATS NIH HHS grantid: UL1 TR002529 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG CO8 COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN ENC EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 Q~Q R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AEFGJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY ALVPJ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 5PM |
| ID | FETCH-LOGICAL-c4814-5e6eb59439a3dc52b61b80bf934b8496e4d4179fac8a0a5c2d7f001ef05328d83 |
| IEDL.DBID | DR2 |
| ISSN | 1085-9489 |
| IngestDate | Thu Aug 21 13:38:45 EDT 2025 Fri Jul 25 06:15:50 EDT 2025 Thu Apr 03 07:05:24 EDT 2025 Tue Jul 01 03:23:58 EDT 2025 Thu Apr 24 22:53:08 EDT 2025 Wed Aug 20 07:25:10 EDT 2025 Wed Oct 30 09:52:51 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | severity vincristine-induced peripheral neuropathy acute lymphoblastic leukemia children patterns |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 Peripheral Nerve Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4814-5e6eb59439a3dc52b61b80bf934b8496e4d4179fac8a0a5c2d7f001ef05328d83 |
| Notes | ark:/67375/WNG-XRJTM3CB-X ArticleID:JNS12114 istex:540E4F0E3FF4C5FA4F0DBB0FF554EE3118D5C7D3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| ORCID | 0000-0002-5334-8719 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jns.12114 |
| PMID | 25977177 |
| PQID | 1688330924 |
| PQPubID | 1086377 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4610712 proquest_journals_1688330924 pubmed_primary_25977177 crossref_primary_10_1111_jns_12114 crossref_citationtrail_10_1111_jns_12114 wiley_primary_10_1111_jns_12114_JNS12114 istex_primary_ark_67375_WNG_XRJTM3CB_X |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-03 March 2015 2015-03-00 2015-Mar 20150301 |
| PublicationDateYYYYMMDD | 2015-03-01 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-03 |
| PublicationDecade | 2010 |
| PublicationPlace | Malden, USA |
| PublicationPlace_xml | – name: Malden, USA – name: United States – name: La Jolla |
| PublicationTitle | Journal of the peripheral nervous system |
| PublicationTitleAlternate | J Peripher Nerv Syst |
| PublicationYear | 2015 |
| Publisher | Wiley Periodicals, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc |
| References | Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-PeriNomS Group (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454-462. Hoffman MC, Mulrooney DA, Steinberger J, Lee J, Baker KS, Ness KK (2013). Deficits in physical function among young childhood cancer survivors. J Clin Oncol 31:2799-2805. Kumar N (2007). Nutritional neuropathies. Neurol Clin 25:209-255. Gomber S, Dewan P, Chhonker D (2010). Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 77:97-100. Liew E, Thyagu S, Atenafu EG, Alibhai SM, Brandwein JM (2013). Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol. Leuk Res 37:1632-1635. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ (1993). Long-term effects of vincristine on the peripheral nervous system. J Neurooncol 15:23-27. Gilchrist LS, Marais L, Tanner L (2014). Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer 22:359-366. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD (2006). Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, Bostrom BC, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium (2012). Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 120:285-290. Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, Srivastava DK, Robison LL, Hudson MM, Gurney JG (2013). Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St Jude Lifetime Cohort study. Arch Phys Med Rehabil 94:1451-1457. Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL, Pui C (2011). Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:1147-1153. Griffith K, Merkies ISJ, Hill E, Cornblath D (2010). Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15:314-325. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC (2010). Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Pediatr Blood Cancer 55:254-259. Hockenberry MJ (Ed) (2005). Wong's Essentials of Pediatric Nursing, 7th Edn. Elsevier Mosby, St. Louis, pp 1307. Khan RB, Hudson MM, Ledet DS, Morris EB, Pui CH, Howard SC, Krull KR, Hinds PS, Crom D, Browne E, Zhu L, Rai S, Srivastava D, Ness KK (2014). Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study. J Cancer Surviv 8:688-96. Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D'Angelo P, Di Cataldo A, Carli M (2005). The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Grou. Cancer 103:1719-1724. Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, Gurney JG (2009). Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184-189. Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J (2013). Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 6:E49-60. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479-494. Egbelakin A, Ferguson M, MacGill E, Lehmann A, Topletz A, Quinney S, Li L, McCammack K, Hall S, Renbarger J (2011). Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361-367. Gilchrist LS, Tanner L (2013). The pediatric-modified Total Neuropathy Score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 21:847-856. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53:1660-1664. Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaletti G (2011). Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity Scale. J Peripher Nerv Syst 16:228-236. Gilchrist L (2012). Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Semin Pediatr Neurol 19:9-17. Bosenberg A, Thomas J, Lopez T, Kokinsky E, Larsson LE (2003). Validation of a six-graded faces scale for evaluation of postoperative pain in children. Paediatr Anaesth 13:708-713. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B, Pediatric Oncology Group S (2003). Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 25:316-320. Kaufman L, Rousseeuw P (1987). Clustering by Means of Medoids, Vol. 3. Faculty of Mathematics and Informatics, Delft University of Technology. Toopchizadeh V, Barzegar M, Rezamand A, Feiz AH (2009). Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study. J Pediatr Neurol 7:351-356. Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE (2015). Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815-823. Paice JA (2009). Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25:S8-S19. American Cancer Society (2014). Cancer Facts & Figures 2014. http://www.cancer.org. Accessed February 26, 2015. Smith EL, Beck SL, Cohen J (2008). The total neuropathy score (TNS): a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35:96-102. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005). Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076-1077. Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2000). Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279. Vats T, Buchanan G, Mehta P, Ragab A, Hvizdale E, Nitschke R, Link M, Beardsley GP, Maybee D, Krischer J (1992). A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. Invest New Drugs 10:231-234. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51-77. 2012; 82 2010; 77 2010; 55 2009; 25 1987; 3 2012; 120 2010; 15 2006; 34 2013; 21 2013; 24 2000; 46 2003; 13 2005; 64 2012; 19 2008; 35 2011; 57 2005 2011; 56 2011; 16 1992; 10 2013; 6 2014; 22 1993; 15 2009; 14 2013; 37 2010; 46 2015; 313 2005; 103 2013; 94 2013; 31 2003; 25 1999; 53 2009; 7 2014 2013 2014; 8 2007; 25 1998; 9 Kaufman L (e_1_2_6_23_1) 1987 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 American Cancer Society (e_1_2_6_3_1) 2014 e_1_2_6_20_1 e_1_2_6_9_1 Hockenberry MJ (e_1_2_6_21_1) 2005 e_1_2_6_8_1 Toopchizadeh V (e_1_2_6_37_1) 2009; 7 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_29_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
| References_xml | – reference: Gomber S, Dewan P, Chhonker D (2010). Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 77:97-100. – reference: Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D'Angelo P, Di Cataldo A, Carli M (2005). The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Grou. Cancer 103:1719-1724. – reference: Smith EL, Beck SL, Cohen J (2008). The total neuropathy score (TNS): a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35:96-102. – reference: Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, Srivastava DK, Robison LL, Hudson MM, Gurney JG (2013). Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St Jude Lifetime Cohort study. Arch Phys Med Rehabil 94:1451-1457. – reference: Paice JA (2009). Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25:S8-S19. – reference: Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744. – reference: Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, Gurney JG (2009). Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184-189. – reference: Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC (2010). Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Pediatr Blood Cancer 55:254-259. – reference: Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE (2015). Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815-823. – reference: Khan RB, Hudson MM, Ledet DS, Morris EB, Pui CH, Howard SC, Krull KR, Hinds PS, Crom D, Browne E, Zhu L, Rai S, Srivastava D, Ness KK (2014). Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study. J Cancer Surviv 8:688-96. – reference: Kaufman L, Rousseeuw P (1987). Clustering by Means of Medoids, Vol. 3. Faculty of Mathematics and Informatics, Delft University of Technology. – reference: Gilchrist L (2012). Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Semin Pediatr Neurol 19:9-17. – reference: Gilchrist LS, Tanner L (2013). The pediatric-modified Total Neuropathy Score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 21:847-856. – reference: Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53:1660-1664. – reference: Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J (2013). Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 6:E49-60. – reference: Toopchizadeh V, Barzegar M, Rezamand A, Feiz AH (2009). Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study. J Pediatr Neurol 7:351-356. – reference: Bosenberg A, Thomas J, Lopez T, Kokinsky E, Larsson LE (2003). Validation of a six-graded faces scale for evaluation of postoperative pain in children. Paediatr Anaesth 13:708-713. – reference: Egbelakin A, Ferguson M, MacGill E, Lehmann A, Topletz A, Quinney S, Li L, McCammack K, Hall S, Renbarger J (2011). Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361-367. – reference: Gilchrist LS, Marais L, Tanner L (2014). Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer 22:359-366. – reference: Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479-494. – reference: Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B, Pediatric Oncology Group S (2003). Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 25:316-320. – reference: Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-PeriNomS Group (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454-462. – reference: Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005). Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076-1077. – reference: Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD (2006). Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327. – reference: Vats T, Buchanan G, Mehta P, Ragab A, Hvizdale E, Nitschke R, Link M, Beardsley GP, Maybee D, Krischer J (1992). A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. Invest New Drugs 10:231-234. – reference: Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ (1993). Long-term effects of vincristine on the peripheral nervous system. J Neurooncol 15:23-27. – reference: Hockenberry MJ (Ed) (2005). Wong's Essentials of Pediatric Nursing, 7th Edn. Elsevier Mosby, St. Louis, pp 1307. – reference: Liew E, Thyagu S, Atenafu EG, Alibhai SM, Brandwein JM (2013). Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol. Leuk Res 37:1632-1635. – reference: Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2000). Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279. – reference: Griffith K, Merkies ISJ, Hill E, Cornblath D (2010). Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15:314-325. – reference: Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51-77. – reference: Kumar N (2007). Nutritional neuropathies. Neurol Clin 25:209-255. – reference: American Cancer Society (2014). Cancer Facts & Figures 2014. http://www.cancer.org. Accessed February 26, 2015. – reference: Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, Bostrom BC, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium (2012). Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 120:285-290. – reference: Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL, Pui C (2011). Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:1147-1153. – reference: Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaletti G (2011). Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity Scale. J Peripher Nerv Syst 16:228-236. – reference: Hoffman MC, Mulrooney DA, Steinberger J, Lee J, Baker KS, Ness KK (2013). Deficits in physical function among young childhood cancer survivors. J Clin Oncol 31:2799-2805. – volume: 3 year: 1987 – volume: 10 start-page: 231 year: 1992 end-page: 234 article-title: A study of toxicity and comparative therapeutic efficacy of vindesine‐prednisone vs. vincristine‐prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study publication-title: Invest New Drugs – volume: 25 start-page: S8 year: 2009 end-page: S19 article-title: Clinical challenges: chemotherapy‐induced peripheral neuropathy publication-title: Semin Oncol Nurs – volume: 82 start-page: 51 year: 2012 end-page: 77 article-title: Chemotherapy‐induced peripheral neurotoxicity (CIPN): an update publication-title: Crit Rev Oncol Hematol – year: 2005 – volume: 31 start-page: 2799 year: 2013 end-page: 2805 article-title: Deficits in physical function among young childhood cancer survivors publication-title: J Clin Oncol – volume: 9 start-page: 739 year: 1998 end-page: 744 article-title: Pitfalls in grading severity of chemotherapy‐induced peripheral neuropathy publication-title: Ann Oncol – volume: 64 start-page: 1076 year: 2005 end-page: 1077 article-title: Dose‐related vincristine‐induced peripheral neuropathy with unexpected off‐therapy worsening publication-title: Neurology – volume: 77 start-page: 97 year: 2010 end-page: 100 article-title: Vincristine induced neurotoxicity in cancer patients publication-title: Indian J Pediatr – volume: 19 start-page: 9 year: 2012 end-page: 17 article-title: Chemotherapy‐induced peripheral neuropathy in pediatric cancer patients publication-title: Semin Pediatr Neurol – volume: 37 start-page: 1632 year: 2013 end-page: 1635 article-title: Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric‐based protocol publication-title: Leuk Res – volume: 56 start-page: 361 year: 2011 end-page: 367 article-title: Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia publication-title: Pediatr Blood Cancer – volume: 22 start-page: 359 year: 2014 end-page: 366 article-title: Comparison of two chemotherapy‐induced peripheral neuropathy measurement approaches in children publication-title: Support Care Cancer – year: 2014 – volume: 46 start-page: 269 year: 2000 end-page: 279 article-title: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91 publication-title: Int J Radiat Oncol Biol Phys – volume: 35 start-page: 96 year: 2008 end-page: 102 article-title: The total neuropathy score (TNS): a tool for measuring chemotherapy‐induced peripheral neuropathy publication-title: Oncol Nurs Forum – volume: 120 start-page: 285 year: 2012 end-page: 290 article-title: Bortezomib with chemotherapy is highly active in advanced B‐precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study publication-title: Blood – volume: 15 start-page: 314 year: 2010 end-page: 325 article-title: Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties publication-title: J Peripher Nerv Syst – volume: 53 start-page: 1660 year: 1999 end-page: 1664 article-title: Total neuropathy score: validation and reliability study publication-title: Neurology – volume: 8 start-page: 688 year: 2014 end-page: 96 article-title: Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross‐sectional study publication-title: J Cancer Surviv – volume: 34 start-page: 1317 year: 2006 end-page: 1327 article-title: Selective metabolism of vincristine in vitro by CYP3A5 publication-title: Drug Metab Dispos – volume: 15 start-page: 23 year: 1993 end-page: 27 article-title: Long‐term effects of vincristine on the peripheral nervous system publication-title: J Neurooncol – volume: 16 start-page: 228 year: 2011 end-page: 236 article-title: Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity Scale publication-title: J Peripher Nerv Syst – volume: 13 start-page: 708 year: 2003 end-page: 713 article-title: Validation of a six‐graded faces scale for evaluation of postoperative pain in children publication-title: Paediatr Anaesth – volume: 94 start-page: 1451 year: 2013 end-page: 1457 article-title: Chemotherapy‐related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St Jude Lifetime Cohort study publication-title: Arch Phys Med Rehabil – volume: 46 start-page: 479 year: 2010 end-page: 494 article-title: Chemotherapy‐induced peripheral neurotoxicity assessment: a critical revision of the currently available tools publication-title: Eur J Cancer – volume: 7 start-page: 351 year: 2009 end-page: 356 article-title: Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study publication-title: J Pediatr Neurol – volume: 25 start-page: 209 year: 2007 end-page: 255 article-title: Nutritional neuropathies publication-title: Neurol Clin – volume: 55 start-page: 254 year: 2010 end-page: 259 article-title: Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium publication-title: Pediatr Blood Cancer – volume: 14 start-page: 184 year: 2009 end-page: 189 article-title: Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia publication-title: J Peripher Nerv Syst – volume: 57 start-page: 1147 year: 2011 end-page: 1153 article-title: Neuropathic pain during treatment for childhood acute lymphoblastic leukemia publication-title: Pediatr Blood Cancer – volume: 21 start-page: 847 year: 2013 end-page: 856 article-title: The pediatric‐modified Total Neuropathy Score: a reliable and valid measure of chemotherapy‐induced peripheral neuropathy in children with non‐CNS cancers publication-title: Support Care Cancer – volume: 6 start-page: E49 year: 2013 end-page: 60 article-title: Measuring vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia publication-title: Cancer Nurs – volume: 25 start-page: 316 year: 2003 end-page: 320 article-title: Vincristine‐induced neuropathy as the initial presentation of Charcot‐Marie‐Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study publication-title: J Pediatr Hematol Oncol – volume: 24 start-page: 454 year: 2013 end-page: 462 article-title: The chemotherapy‐induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings publication-title: Ann Oncol – volume: 313 start-page: 815 year: 2015 end-page: 823 article-title: Association of an inherited genetic variant with vincristine‐related peripheral neuropathy in children with acute lymphoblastic leukemia publication-title: JAMA – volume: 103 start-page: 1719 year: 2005 end-page: 1724 article-title: The IVADo regimen – a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Grou publication-title: Cancer – year: 2013 – ident: e_1_2_6_33_1 doi: 10.1023/A:1008344507482 – volume-title: Clustering by Means of Medoids year: 1987 ident: e_1_2_6_23_1 – ident: e_1_2_6_20_1 doi: 10.1111/j.1529-8027.2010.00292.x – ident: e_1_2_6_38_1 doi: 10.1007/BF00877252 – ident: e_1_2_6_36_1 doi: 10.1097/NCC.0b013e318299ad23 – ident: e_1_2_6_6_1 doi: 10.1002/cncr.20928 – ident: e_1_2_6_12_1 doi: 10.1124/dmd.106.009902 – ident: e_1_2_6_32_1 doi: 10.1007/BF01050259 – volume-title: Wong's Essentials of Pediatric Nursing year: 2005 ident: e_1_2_6_21_1 – ident: e_1_2_6_31_1 doi: 10.1016/j.soncn.2009.03.013 – ident: e_1_2_6_9_1 doi: 10.1093/annonc/mds329 – ident: e_1_2_6_34_1 doi: 10.1111/j.1529-8027.2009.00230.x – ident: e_1_2_6_30_1 doi: 10.1016/j.apmr.2013.03.009 – ident: e_1_2_6_13_1 doi: 10.1001/jama.2015.0894 – ident: e_1_2_6_11_1 doi: 10.1212/WNL.53.8.1660 – ident: e_1_2_6_25_1 doi: 10.1016/S0360-3016(99)00369-7 – ident: e_1_2_6_7_1 doi: 10.1046/j.1460-9592.2003.01142.x – ident: e_1_2_6_18_1 doi: 10.1007/s00520-013-1981-6 – ident: e_1_2_6_16_1 doi: 10.1016/j.spen.2012.02.011 – ident: e_1_2_6_28_1 doi: 10.1002/pbc.22456 – ident: e_1_2_6_2_1 – volume: 7 start-page: 351 year: 2009 ident: e_1_2_6_37_1 article-title: Electrophysiological consequences of vincristine contained chemotherapy in children: a cohort study publication-title: J Pediatr Neurol – ident: e_1_2_6_14_1 doi: 10.1002/pbc.22845 – ident: e_1_2_6_17_1 doi: 10.1007/s00520-012-1591-8 – ident: e_1_2_6_39_1 doi: 10.1212/01.WNL.0000154642.45474.28 – ident: e_1_2_6_8_1 doi: 10.1016/j.ejca.2009.12.008 – ident: e_1_2_6_27_1 doi: 10.1016/j.leukres.2013.09.018 – ident: e_1_2_6_5_1 doi: 10.1016/j.critrevonc.2011.04.012 – ident: e_1_2_6_10_1 doi: 10.1097/00043426-200304000-00010 – ident: e_1_2_6_24_1 doi: 10.1007/s11764-014-0375-1 – volume-title: Cancer Facts & Figures 2014 year: 2014 ident: e_1_2_6_3_1 – ident: e_1_2_6_19_1 doi: 10.1007/s12098-009-0254-3 – ident: e_1_2_6_26_1 doi: 10.1016/j.ncl.2006.11.001 – ident: e_1_2_6_4_1 doi: 10.1002/pbc.23039 – ident: e_1_2_6_35_1 doi: 10.1188/08.ONF.96-102 – ident: e_1_2_6_15_1 doi: 10.1111/j.1529-8027.2011.00351.x – ident: e_1_2_6_22_1 doi: 10.1200/JCO.2012.47.8081 – ident: e_1_2_6_29_1 doi: 10.1182/blood-2012-04-418640 |
| SSID | ssj0017919 |
| Score | 2.4568229 |
| Snippet | Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine‐induced... Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia ( ALL ), can lead to vincristine‐induced... Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine-induced... |
| SourceID | pubmedcentral proquest pubmed crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 37 |
| SubjectTerms | Academic grading acute lymphoblastic leukemia Adolescent Antineoplastic Agents, Phytogenic - adverse effects Child Child, Preschool children Female Humans Infant Leukemia Male Medical treatment Pain Measurement patterns Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy severity Severity of Illness Index Vincristine - adverse effects vincristine-induced peripheral neuropathy |
| Title | Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia |
| URI | https://api.istex.fr/ark:/67375/WNG-XRJTM3CB-X/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjns.12114 https://www.ncbi.nlm.nih.gov/pubmed/25977177 https://www.proquest.com/docview/1688330924 https://pubmed.ncbi.nlm.nih.gov/PMC4610712 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Za9wwEIBFSKH0pUfSwzmKKCX0xWFtS7ZMn5LQNCzsUtKE7kPB6DI1u9GWPUK2T_0J_Y39JZ2RD7JtCqV-MngsLGmkGcmjbwh5DTY114LJUIBxCJnORSjBsoZc89TESclUhgecB8P07JL1R3y0Qd62Z2FqPkS34YYjw8_XOMClmt8e5NApyCdDFijGaqFDdN6ho5C6mbfB9TkTeUMV8lE87ZtrtugeNuvNXY7mn_GSt_1Yb4hOH5HPbRXq-JPx4XKhDvW33-iO_1nHx-Rh46DSo1qjnpAN67bI9pGDxfnVih5QHzLq9-K3yP1B82d-m8w-eFCnm1PpDAVzazErHp2W9Lpy2s8kzv78_qNyBpTJUAQse6LBhHqkJmZGXtHK0fZ0OcUdYir1cmHpZAU6N1Xg6MNH0Yldju1VJZ-Sy9N3FydnYZPPIdRMRCzkNrWK5-ACycRoHqs0UqKnyjxhSrA8tcxgPrRSaiF7kuvYZCX0pC0xe4UwInlGNt3U2ReEShvr0iSsV8qSZblRHC6YoJSRkRacBeRN27OFbmDnmHNjUnSLHjcvfNMG5FUn-rUmfNwldODVo5OQszGGxGW8-DR8X4zO-xeD5OS4GAVkr9WfopkNoIgUUzr3YKkbkOe1KnUFxQgAjLIsINmaknUCyP9ef-KqL54Djqj8LIqhrl6H_v71RX_40d_s_LvoLnkAviGvw-32yOZitrT74H8t1Es_0H4B06IvnA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbhMxFL0qrQRseLQ8BgpYCCo2U2Vm7BnPgkVpKWnaRKikIrvBrxGjpA7KAwgrPoEP4Vf4Cb4E2_NQA0Vi0wVZjZQry-P7tOf6HIAnJqemgmLmU5McfCxS6jOTWX0iSCzDKMc8sRecu724fYI7AzJYge_1XZgSH6I5cLOe4eK1dXB7IH3Wy41WLEAZrloqD9Xik9mwTZ8f7BntPg3D_Zf93bZfcQr4AtMA-0TFipPUpGEWSUFCHgectnieRphTnMYKS8vJlTNBWYsREcokN5Fc5ZZBgUoamXEvwZplELdI_XvHDViVxflM63b-FNO0wjFyfUP1VJey35pV5OfzSts_OzTPVs4u9e1fhx_1opUdL8Pt-Yxviy-_4Un-L6t6A65VNTjaKZ3mJqwovQ4bO5rNxqcLtIVcV6z73LAOl7tV88EGTF47LFI9RUxLZCoKZYn_0DhHHwstXLDU6ufXb4WWxl8kshjSDrRhhBxqqCV_XqBCo_oCPbKH4IiJ-Uyh0cK41ZibvYyZFBqp-VCdFuwWnFzIQtyGVT3W6i4gpkKRywi3cpbjJJWcmJ-JwVyyQFCCPXhWm1ImKjx3Sysyypp9nZ5mTpUePG5EP5QgJucJbTl7bCTYZGi7_hKSve29ygbHnX432n2RDTzYrA02qwKeGSK2rNUts5v34E5pu81AocU4DJLEg2TJqhsBC3G-_I8u3juoc8sGkASheVdntH-ffdbpvXEP9_5d9BFcafe7R9nRQe_wPlw1pTApuws3YXU2masHptyc8YfOyxG8u2gH-AVNOIzr |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbhMxFL0qrVSxodDymFLAQlCxmSozY894FixKQ2hTElWlFdlN_RoRJXWqPICw4hP4D36Fr-BLsD0PNVAkNl2QVaRcWY59X545PgfgmampqaCY-dQUBx-LlPrMVFafCBLLMMoxT-wF50433j_F7R7pLcH36i5MwQ9RP3CzkeHytQ3wC5lfDnKzKZafDJeIykM1_2TOa5OXB02zuc_DsPX6ZG_fLyUFfIFpgH2iYsVJaqowi6QgIY8DThs8TyPMKU5jhaWV5MqZoKzBiAhlkptErnIroEAljcy4N2AFx43U6kQ0j2uuKkvzmVZo_hTTtKQxcrChaqoLxW_F7uPnqzrbPwGalxtnV_laa_CjWrMC8DLYmU35jvjyG53kf7Kot-FW2YGj3SJk7sCS0uuwsavZdHQ-R9vIYWLdy4Z1WO2U0IMNGB85JlI9QUxLZPoJZWX_0ChHH_tauFSp1c-v3_pammiRyDJIO8qGIXKcoVb6eY76GlXX55F9BI6YmE0VGs5NUI24OcmYSaGhmg3UeZ_dhdNrWYh7sKxHWj0AxFQochnhRs5ynKSSE_MxGZhLFghKsAcvKk_KRMnmbkVFhll9qtOTzG2lB09r04uCwuQqo23njrUFGw8s5i8h2fvum6x33D7pRHuvsp4HW5W_ZmW6M0PEVrO6Yc7yHtwvXLceKLQMh0GSeJAsOHVtYAnOF3_R_Q-O6NxqASRBaP6r89m_zz5rd9-5L5v_bvoEVo-areztQffwIdw0fTApoIVbsDwdz9Qj02tO-WMX4wjOrtv_fwEX8oua |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patterns+and+severity+of+vincristine-induced+peripheral+neuropathy+in+children+with+acute+lymphoblastic+leukemia&rft.jtitle=Journal+of+the+peripheral+nervous+system&rft.au=Smith%2C+Ellen+M.+Lavoie&rft.au=Li%2C+Lang&rft.au=Chiang%2C+ChienWei&rft.au=Thomas%2C+Karin&rft.date=2015-03-01&rft.issn=1085-9489&rft.eissn=1529-8027&rft.volume=20&rft.issue=1&rft.spage=37&rft.epage=46&rft_id=info:doi/10.1111%2Fjns.12114&rft_id=info%3Apmid%2F25977177&rft.externalDocID=PMC4610712 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1085-9489&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1085-9489&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1085-9489&client=summon |